Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015393 | 1.00 | LMNA (0.41) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL25015392 | 1.00 | LMNA (0.41) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL14667152 | 0.81 | APLNR (0.32) | APLNR | |
| SCHEMBL25015746 | 0.81 | — | — | |
| SCHEMBL5035847 | 0.79 | — | — | |
| SCHEMBL1872649 | 0.79 | — | — | |
| SCHEMBL116683 | 0.79 | — | — | |
| SCHEMBL25015745 | 0.79 | — | — | |
| SCHEMBL22487977 | 0.78 | LMNA (0.41) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL31320031 | 0.77 | GABRA5 (0.44) | LMNACYP3A4GABRA1TSHRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | LMNA 1952/4885CYP3A4 4463/4885GABRA1 3635/4885 |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | LMNA 1952/4885CYP3A4 4463/4885GABRA1 3635/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | LMNA 2015/4885CYP3A4 422/4885GABRA1 362/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | LMNA 1952/4885CYP3A4 4463/4885GABRA1 3635/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | LMNA 1952/4885CYP3A4 4463/4885GABRA1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.